1.
Drugs Context
; 8: 212599, 2019.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31402931
RESUMO
Hypoglycaemia is the more frequent complication of insulin therapy and the main barrier to tight glycaemic control. Injectable glucagon and oral intake of carbohydrates are the recommended treatments for severe and non-severe hypoglycaemia episodes, respectively. Nasal glucagon is currently being developed as a ready-to-use device, to simplify severe hypoglycaemia rescue. Stable forms of liquid glucagon could open the field for different approaches for mild to moderate hypoglycaemia treatment, such as mini-doses of glucagon or continuous subcutaneous glucagon infusion as a part of dual-hormone closed-loop systems. Pharmaceutical companies are developing stable forms of native glucagon or glucagon analogues for that purpose.
2.
Acta Diabetol
; 55(10): 1083-1085, 2018 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29987593
Assuntos
Glicemia/metabolismo , Diabetes Mellitus Tipo 1/tratamento farmacológico , Diabetes Mellitus Tipo 1/cirurgia , Adulto , Cesárea , Feminino , Humanos , Hipoglicemia/metabolismo , Hipoglicemia/prevenção & controle , Hipoglicemiantes/administração & dosagem , Insulina/administração & dosagem , Sistemas de Infusão de Insulina , Gravidez
3.
Diabetes Technol Ther
; 16(2): 123-4, 2014 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24160691